New research: Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for #oesophagealcancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trial
https://t.co/7pQ9KeJYnQ
🔥Hot off the press🔥 from Kyoto. Neoadjuvant chemoradiotherapy is associated with better RFS among patients with positive mrEMVI.
https://t.co/BK4OltkS94
🔥Hot off the press!!
Cyclin-Dependent Kinase 4/6 Inhibition as a Novel Therapy for Peritoneal Mucinous Carcinomatosis With GNAS Mutations | Journal of Clinical Oncology
https://t.co/hJuEZZZ5ET
@ASCO abstract titles released! See you all in AM on June 3rd at the Poster hall @McCormick_Place in Chicago #ASCO23 I'll present our work (#2614) on associations of IDO1 with immune markers as well as it's impact on survival of immune checkpoint inhibitors. #PrecisionMedicine
Mortality of Patients With Metastatic Colorectal Cancer Randomized to Systemic Treatment vs Primary Tumor... https://t.co/DJM8a1TxzA via @JAMASurgery part of @JAMANetwork
🆕JCOG0603
"Hepatectomy Followed by mFOLFOX6 Versus Hepatectomy Alone for Liver-Only Metastatic Colorectal Cancer (JCOG0603): A Phase II or III Randomized Controlled Trial" was published in JCO!
https://t.co/ldSdpqST7T
#ColorectalCancer#JCO@ASCO@ASCO_pubs#JCOG
It is with considerable regret that @cochranecollab's Governing Board announces the cancellation of Cochrane Colloquium Toronto which had been rescheduled for 11-14th September, 2022. https://t.co/ZQcw41Od8z @CochraneCanada
HR is the mainstream, but RMST is easy to interpret. Would it be a new standard?
Using the Restricted Mean Survival Time Difference as an Alternative to the Hazard Ratio for Analyzing Clinical Car… https://t.co/iWiufJ2Dwk
"With the deepest disappointment and regret I have to inform you that as a result of the continued spread and impact of the COVID-19 across the world, Cochrane’s 27th Colloquium in Toronto, Canada, between 4th-7th October this year has been cancelled." https://t.co/JHuW6bOq9V